Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Silvia Novello(University of Turin), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Mahmut Gümüş(Istanbul Medeniyet University), Alexander Golf, Paul Schwarzenberger(Merck & Co., Inc., Rahway, NJ, USA (United States)), Julien Mazières(Université Toulouse III - Paul Sabatier), Ying Cheng(Jilin Province Tumor Hospital), Andrew Robinson(University of California, Riverside), Alexander Luft(Leningrad Regional Cancer Center), M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Ali Tafreshi, Shunichi Sugawara(Sendai Kousei Hospital), Balázs Halmos(Montefiore Medical Center), David Vicente(Université Toulouse III - Paul Sabatier), Erin Jensen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ki Hyeong Lee(Chungbuk National University Hospital)
Cited by 541
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k